RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals Net Income 2024

EPIRUS Biopharmaceuticals Net Income

-138.35 M USD

Ticker

EPRSQ

ISIN

US29428P1075

WKN

A117U3

In 2024, EPIRUS Biopharmaceuticals's profit amounted to -138.35 M USD, a 54.75% increase from the -89.4 M USD profit recorded in the previous year.

The EPIRUS Biopharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2017e-
2016e-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-
2003-
2002-
2001-
2000-

EPIRUS Biopharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into EPIRUS Biopharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by EPIRUS Biopharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects EPIRUS Biopharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of EPIRUS Biopharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into EPIRUS Biopharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing EPIRUS Biopharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on EPIRUS Biopharmaceuticals’s growth potential.

EPIRUS Biopharmaceuticals Revenue, EBIT and net profit per share

DateEPIRUS Biopharmaceuticals RevenueEPIRUS Biopharmaceuticals EBITEPIRUS Biopharmaceuticals Net Income
2017e0 undefined0 undefined0 undefined
2016e0 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined
20020 undefined0 undefined0 undefined
20010 undefined0 undefined0 undefined
20000 undefined0 undefined0 undefined

EPIRUS Biopharmaceuticals stock margins

The EPIRUS Biopharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EPIRUS Biopharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EPIRUS Biopharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the EPIRUS Biopharmaceuticals's sales revenue. A higher gross margin percentage indicates that the EPIRUS Biopharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the EPIRUS Biopharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the EPIRUS Biopharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the EPIRUS Biopharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the EPIRUS Biopharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the EPIRUS Biopharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

EPIRUS Biopharmaceuticals Margin History

EPIRUS Biopharmaceuticals Gross marginEPIRUS Biopharmaceuticals Profit marginEPIRUS Biopharmaceuticals EBIT marginEPIRUS Biopharmaceuticals Profit margin
2017e0 %0 %0 %
2016e0 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %
20030 %0 %0 %
20020 %0 %0 %
20010 %0 %0 %
20000 %0 %0 %

EPIRUS Biopharmaceuticals Aktienanalyse

What does EPIRUS Biopharmaceuticals do?

EPIRUS Biopharmaceuticals Inc is an American biotech company specializing in the development of innovative drugs for the treatment of cancer and autoimmune diseases. It was founded in 2010 by Amit Munshi and is headquartered in Boston, Massachusetts. The company's business model is based on the use of biotechnology and advanced research and development to create specialized medications. EPIRUS aims to help patients with serious medical needs and contribute to improving healthcare worldwide. EPIRUS Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding EPIRUS Biopharmaceuticals's Profit Margins

The profit margins of EPIRUS Biopharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of EPIRUS Biopharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating EPIRUS Biopharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

EPIRUS Biopharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When EPIRUS Biopharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about EPIRUS Biopharmaceuticals stock

How much profit has EPIRUS Biopharmaceuticals made this year?

EPIRUS Biopharmaceuticals has made -138.35 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 54.75% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does EPIRUS Biopharmaceuticals publish its earnings?

EPIRUS Biopharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of EPIRUS Biopharmaceuticals?

The profits of EPIRUS Biopharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of EPIRUS Biopharmaceuticals?

You can learn more about the earnings of EPIRUS Biopharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does EPIRUS Biopharmaceuticals pay?

Over the past 12 months, EPIRUS Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EPIRUS Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EPIRUS Biopharmaceuticals?

The current dividend yield of EPIRUS Biopharmaceuticals is .

When does EPIRUS Biopharmaceuticals pay dividends?

EPIRUS Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EPIRUS Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EPIRUS Biopharmaceuticals located?

EPIRUS Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EPIRUS Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EPIRUS Biopharmaceuticals from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did EPIRUS Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of EPIRUS Biopharmaceuticals in the year 2023?

In the year 2023, EPIRUS Biopharmaceuticals distributed 0 USD as dividends.

In which currency does EPIRUS Biopharmaceuticals pay out the dividend?

The dividends of EPIRUS Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EPIRUS Biopharmaceuticals

Our stock analysis for EPIRUS Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EPIRUS Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.